JAK Inhibitors in the Evolving Treatment Landscape of Atopic Dermatitis - Episode 9

Utilizing JAK Inhibitors in Clinical Practice

Published on: 
, , ,

Dermatology experts discuss the use of JAK inhibitors in clinical practice, highlighting their own experiences and use of JAKs alongside corticosteroids.

This is a video synopsis/summary of a panel discussion involving Christopher Bunick, MD, PhD; Peter Lio, MD; Lisa Swanson, MD, PhD; and Alexandra Golant, MD.

Dr Lio shares his overwhelmingly positive experience with Janus kinase (JAK) inhibitors in treating atopic dermatitis (AD) since their approval. Patients have responded reliably and quickly, often achieving a new level of improvement previously unseen. He emphasizes the importance of the heterogeneity of individual patient responses and notes that almost every patient he has treated with JAK inhibitors has responded well.

Regarding dosing, Dr Lio primarily uses the starting dose for most patients, with only a few requiring adjustment. He even mentions the strategy of lowering the dose after achieving good control to minimize exposure, highlighting the flexibility of JAK inhibitors.

The discussion then shifts to switching from biologics to JAK inhibitors, a common scenario in Dr Lio's clinic. He notes the reliable and impressive clinical improvement in patients transitioning from biologics to JAK inhibitors, especially for those experiencing a decline in response or never achieving the desired outcome with biologics.

Dr Lio introduces the atopic dermatitis control tool (ADCT), a validated patient-reported outcomes survey that aids in assessing patient control. The ADCT, a concise set of questions taking less than a minute to complete, has been instrumental in revealing patients' true experiences and motivating them to seek better control.

The conversation concludes with insights into the evolving standards of care in AD treatment, acknowledging the current era's remarkable achievements in efficacy, safety, and patient-reported outcomes. Dr Lio expresses excitement about the ongoing transformation in AD management and the prospect of achieving stringent endpoints, ultimately improving patients' quality of life. The discussion also touches on the evolving landscape of clinical trials in AD, aligning with the higher metrics and expectations set by advanced therapies like JAK inhibitors.

Video synopsis is AI-generated and reviewed by HCPLive editorial staff.